MARKET WIRE NEWS

Progyny (PGNY) Q4 2025 Earnings Call Transcript

Source: Motley Fool

2026-02-26 18:25:34 ET

Image source: The Motley Fool.

Thursday, Feb. 26, 2026 at 4:45 p.m. ET

Progyny (NASDAQ:PGNY) ended fiscal 2025 with record revenue and adjusted EBITDA, with both measures surpassing guidance midpoints by meaningful margins. The company’s diversified client base and nearly complete client retention were highlighted as supporting operational stability, while platform investments and cost control drove improved gross margins. Management expects continued growth in fiscal 2026, supported by client expansion and service enhancements, yet has proactively acknowledged possible member activity variability and a smaller-than-expected covered lives count, attributed to administrative updates from clients, not workforce reductions. Guidance for fiscal 2026 also details a pronounced reduction in stock-based compensation, and new product launches, particularly Progyny Select, are structured to limit risk but are not expected to impact results until fiscal 2027.

Continue reading

Progyny Inc.

NASDAQ: PGNY

PGNY Trading

-19.04% G/L:

$17.43 Last:

3,353,203 Volume:

$19.88 Open:

mwn-ir Ad 300

PGNY Latest News

February 26, 2026 06:25:34 pm
Progyny (PGNY) Q4 2025 Earnings Call Transcript

PGNY Stock Data

$1,856,999,027
78,107,759
1.06%
116
N/A
Healthcare Providers & Services
Healthcare
US
New York

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App